Timing, method and discontinuation of hydrocortisone administration for septic shock patients

Table 4 Univariate and multivariate logistic regression analysis for relevant factors associated with shock reversal

Variable	Univariate		P value	Multivariate	P value
	Shock reversal (n = 30)	No-reversal (n = 29)		Adjusted OR (95%CI)
Age (yr), SD	53 ± 16.3	50 ± 16.3	0.46
Male gender, n (%)	15 (36.6)	11 (61.1)	0.08	1.4 (0.21-10.1)	0.68
Medical disease, n (%)	11 (26.8)	6 (33.3)	0.61
Oncologic disease, n (%)	20 (48.8)	5 (27.8)	0.13	1.0 (0.18-6.3)	0.92
AKI, n (%)	17 (41.5)	14 (77.8)	0.01	0.3 (0.05-2.0)	0.23
ARDS, n (%)	12 (29.3)	9 (50)	0.12	2.7 (0.4-16.9)	0.27
Superinfection, n (%)	5 (12.2)	3 (16.7)	0.68
APACHE II score (SD)	20 ± 5.4	23 ± 6.4	0.16	1.1 (0.9-1.3)	0.18
SOFA score (SD)	10 ± 3.0	10 ± 2.4	0.69
Vasopressin use, n (%)	10 (24.4)	6 (33.3)	0.48	2.5 (0.4-15.4)	0.31
Early hydrocortisone ( ≤ 13 h from NE), n (%)	28 (68.3)	2 (11.1)	0.0001	13.8 (1.4-129)	0.02
NE dose at hydrocortisone initiation ≤ 0.28 μg/kg per minute, n (%)	28 (68.3)	2 (11.1)	0.0001	32.4 (2.7-382)	0.005

Goodness-of-fit (Hosmer-Lemeshow). χ² = 7.01, P = 0.53; AUC, 0.91 (0.80-0.96), P≤ 0.0001. AKI: Acute kidney injury: APACHE II: Acute physiology and chronic health evaluation; ARDS: Acute respiratory distress syndrome; NE: Norepinephrine; SOFA: Sequential organ failure assessment.